All News

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.

The FDA approval of ropeginterferon alfa-2b may lead to longer and better outcomes in essential thrombocythemia, according to Ruben Mesa, MD, FACP.

Matthew Matasar, MD, weighed the optimism and uncertainty surrounding AI’s expanding role in cancer drug discovery and clinical practice.

Radiopharmaceutical therapy currently falls somewhere between localized treatment and systemic therapy, according to Mallika Marar, MD, MBA.

The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09.

Updated HERIZON-GEA-01 survival data show zanidatamab-based regimens outperformed trastuzumab/chemotherapy in first-line HER2-positive advanced GEA.

Matteo S. Carlino, MD, PhD, FRACP, discussed V940 plus pembrolizumab data, safety, and administration in resected melanoma.

The regulatory decision for JBS-003 is intended to help guide personalized radiation de-escalation in patients with HPV-positive oropharyngeal cancer.

Experts highlight the origins and significance of World Radiotherapy Awareness Day and discuss global access challenges surrounding modern radiation oncology.

Rethinking dose fractions and managing subclinical renal and marrow toxicity represent ongoing challenges associated with the use of radiopharmaceutical therapy.

Matthew Matasar, MD, discussed an AI-embedded deterioration index study, Epic’s patient-facing chatbot, and how AI is already absorbing routine documentation work.

AI is intended to assist physicians, giving them more time for interpersonal engagement with patients, according to Nevine Hanna, MD, MPH, FACRO, DABR.

Updated interim PYNNACLE trial data showed a 46% response rate with rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer.

Tumor-informed ctDNA testing with the Signatera assay outperformed standard PET/CT imaging across B- and T-cell lymphoma subtypes.

Data from the phase 3 SENTRY trial support the supplemental new drug application for selinexor plus ruxolitinib in patients with myelofibrosis.

Matteo S. Carlino, MD, PhD, FRACP, discussed immune-related adverse event rates with V940 added to pembrolizumab.

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.

Final COMBI-I data show a survival advantage with spartalizumab plus dabrafenib/trametinib over dabrafenib/trametinib alone in BRAF V600-mutant melanoma.

Matthew Matasar, MD, outlined his wish list for AI in oncology, and detailed AI-bolstered tools already active across his 14-hospital health system.

Savolitinib/osimertinib significantly improved progression-free survival vs osimertinib alone as first-line treatment in the phase 3 SANOVO trial.

BioNTech has terminated a phase 2 trial of autogene cevumeran in ctDNA-positive, resected colorectal cancer after a DSMB found an overall survival imbalance.

Matteo S. Carlino, MD, PhD, FRACP, reviewed efficacy data for V940 plus pembrolizumab in resected melanoma.

Data from the phase 3 SURPASS ET trial supported the approval of ropeginterferon alfa-2b-njft for those with essential thrombocythemia.

Daniel C. McFarland, DO, and Xiomara Rocha-Cadman, MD, discussed why oncologist well-being depends on reflection, mentorship, and peer connection.

Matthew Matasar, MD, explained why AI-assisted digital pathology may meaningfully improve diagnostic precision in hematologic malignancies.

ASCO’s first living guideline for recurrent ovarian cancer recommends platinum-based doublets, selective bevacizumab, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease.

Matthew Matasar, MD, provided practical advice for oncologists who want to start testing generative AI and RAG tools in their own practice.

The FDA granted fast track designation to the ADC SOT106 for soft tissue sarcoma, with a first-in-human trial planned this year.

Results from the phase 3 VERIFY trial led to the approval of rusfertide in polycythemia vera.

Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma.